1. Home
  2. ORMP vs ENTX Comparison

ORMP vs ENTX Comparison

Compare ORMP & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oramed Pharmaceuticals Inc.

ORMP

Oramed Pharmaceuticals Inc.

HOLD

Current Price

$4.32

Market Cap

141.3M

Sector

Health Care

ML Signal

HOLD

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.24

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORMP
ENTX
Founded
2002
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.3M
62.6M
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
ORMP
ENTX
Price
$4.32
$1.24
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
166.2K
124.1K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
6.51%
N/A
EPS Growth
412.50
N/A
EPS
1.50
0.07
Revenue
$2,000,000.00
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.10
$17.86
Revenue Growth
49.25
N/A
52 Week Low
$1.98
$0.91
52 Week High
$5.01
$3.22

Technical Indicators

Market Signals
Indicator
ORMP
ENTX
Relative Strength Index (RSI) 56.93 50.46
Support Level $3.21 $1.12
Resistance Level $5.01 $1.37
Average True Range (ATR) 0.23 0.10
MACD 0.04 0.01
Stochastic Oscillator 40.68 53.33

Price Performance

Historical Comparison
ORMP
ENTX

About ORMP Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: